Several approved therapeutic products, which are currently
available as intravenous dosage forms, are being reformulated and evaluated for
subcutaneous administration. Further, many existing drug delivery devices,
including prefilled syringes, pen injectors, autoinjectors, needle-free injectors
and large volume wearable injectors, have been / are being designed for
subcutaneous administration of biologics.
To order this 530+ page report, which features
160+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
The USD 180+ billion (by 2030) financial
opportunity associated with subcutaneous biologics, affiliated drug delivery
systems and subcutaneous formulation technology licensing deals, has been
analyzed across the following segments:
§ Phase
of development
§
Approved
§
Pre-registration & Phase III
§
Phase II & Phase II/III
§ Type
of molecule
§
Cell and gene therapies
§
Monoclonal antibodies
§
Proteins
§
Peptides (recombinant)
§
Vaccines
§
Others
§ Target
therapeutic area
§
Autoimmune disorders
§
Blood disorders
§
Bone disorders
§
Genetic disorders
§
Metabolic disorders
§
Neurological disorders
§
Oncological disorders
§
Respiratory disorders
§
Others
§ Type
of drug delivery system
§
Large volume wearable injectors
§
Autoinjectors
§
Prefilled syringes
§
Needle-free injectors
§
Drug reconstitution systems
§ Revenues
from licensing deals
§
Upfront payments
§
Milestone payments
§ Key
geographical regions
§
North America
§
Europe
§
Asia Pacific
§
Rest of the World
The
Subcutaneous
Biologics, Technologies and Drug Delivery Systems (3rd Edition),
2020-2030”report features the following companies, which we
identified to be key players in this domain:
§ Adocia
§ Ajinomoto
Bio-Pharma Services
§ Arecor
§ Alteogen
§ Ascendis
Pharma
§ Avadel
Pharmaceuticals
§ Camurus
§ Creative
BioMart
§ Creative
Biolabs
§ DURECT
§ Eagle
Pharmaceuticals
§ Halozyme
Therapeutics
§ MedinCell
§ Xeris
Pharmaceuticals
§ Serina
Therapeutics
Table of Contents
1.
Preface
2.
Executive Summary
3.
Introduction
4.
Subcutaneous Biologics: Current
Market Landscape
5.
Case Study: Leading Subcutaneous
Biologics
6.
Subcutaneous Formulation
Technologies: Current Market Landscape
7.
Subcutaneous Formulation
Technology Developers: Company Competitiveness Analysis
8.
Subcutaneous Formulation
Technology Developers: Company Profiles
9.
Partnerships and Collaborations
10. Subcutaneous
Drug Delivery Systems: Current Market Landscape
11. Swot
Analysis
12. Market
Forecast and Opportunity Analysis
13. Concluding
Remarks
14. Executive
Insights
15. Appendix
1: Tabulated Data
16. Appendix
2: List Of Companies And Organization
To purchase a copy,
please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
Contact Details
Gaurav Chaudhary
+1
(415) 800 3415
+44
(122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
